Z

Zynerba Pharmaceuticals Inc
F:6ZY

Watchlist Manager
Zynerba Pharmaceuticals Inc
F:6ZY
Watchlist
Price: 1.26 EUR 2.44% Market Closed
Market Cap: 67.6m EUR

Zynerba Pharmaceuticals Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Zynerba Pharmaceuticals Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zynerba Pharmaceuticals Inc
F:6ZY
Operating Income
-$38.8m
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.9B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$16.1B
CAGR 3-Years
11%
CAGR 5-Years
22%
CAGR 10-Years
19%
Pfizer Inc
NYSE:PFE
Operating Income
$18.3B
CAGR 3-Years
-23%
CAGR 5-Years
12%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Operating Income
$24.5B
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Operating Income
$26.4B
CAGR 3-Years
46%
CAGR 5-Years
34%
CAGR 10-Years
22%
No Stocks Found

Zynerba Pharmaceuticals Inc
Glance View

Market Cap
68m EUR
Industry
Pharmaceuticals

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The company is headquartered in Devon, Pennsylvania and currently employs 28 full-time employees. The company went IPO on 2015-08-05. Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The firm is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. The company has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

6ZY Intrinsic Value
Not Available
Z

See Also

What is Zynerba Pharmaceuticals Inc's Operating Income?
Operating Income
-38.8m USD

Based on the financial report for Jun 30, 2023, Zynerba Pharmaceuticals Inc's Operating Income amounts to -38.8m USD.

What is Zynerba Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
1%

Over the last year, the Operating Income growth was -4%. The average annual Operating Income growth rates for Zynerba Pharmaceuticals Inc have been 6% over the past three years , 1% over the past five years .

Back to Top